

RESEARCH ARTICLE

Open Access



Factors related to outcome of bloodstream infections due to *Candida parapsilosis* complex

Francesco Barchiesi^{1*} , Elena Orsetti¹, Patrizia Osimani³, Carlo Catassi², Fabio Santelli⁴ and Esther Manso⁵

Abstract

Background: Although *Candida albicans* is the most common cause of fungal blood stream infections (BSIs), infections due to *Candida* species other than *C. albicans* are rising. *Candida parapsilosis* complex has emerged as an important fungal pathogen and became one of the main causes of fungemia in specific geographical areas. We analyzed the factors related to outcome of candidemia due to *C. parapsilosis* in a single tertiary referral hospital over a five-year period.

Methods: A retrospective observational study of all cases of candidemia was carried out at a 980-bedded University Hospital in Italy. Data regarding demographic characteristics and clinical risk factors were collected from the patient's medical records. Antifungal susceptibility testing was performed and MIC results were interpreted according to CLSI species-specific clinical breakpoints.

Results: Of 270 patients diagnosed with *Candida* BSIs during the study period, 63 (23 %) were infected with isolates of *C. parapsilosis* complex which represented the second most frequently isolated yeast after *C. albicans*. The overall incidence rate was 0.4 episodes/1000 hospital admissions. All the strains were in vitro susceptible to all antifungal agents. The overall crude mortality at 30 days was 27 % (17/63), which was significantly lower than that reported for *C. albicans* BSIs (42 % [61/146], $p = 0.042$). Being hospitalized in ICU resulted independently associated with a significant higher risk of mortality (HR 4.625 [CI95% 1.015–21.080], $p = 0.048$). Conversely, early CVC removal was confirmed to be significantly associated with a lower risk of mortality (HR 0.299 [CI95% 0.102–0.874], $p = 0.027$). Finally, the type of primary antifungal therapy did not influence the outcome of infection.

Conclusions: Candidemia due to *C. parapsilosis* complex, the second most commonly causative agent of yeast BSIs in our center, is characterized by a non-negligible mortality at 30 days. An early CVC removal is associated with a significant reduced mortality.

Keywords: *Candida parapsilosis* complex, Candidemia, Risk factors, Mortality, Antifungal agents

Background

Candida is an important cause of bloodstream infections (BSIs) and it is the main agent of invasive fungal infection in hospitalized patients [1, 2]. Although *Candida albicans* is the most common cause of invasive candidiasis, infections due to *Candida* species other than *C. albicans* are rising [3, 4]. In particular, *Candida parapsilosis* complex, which includes *C. parapsilosis*

sensu strictu (the most frequent), *Candida orthopsilosis* and *Candida metapsilosis*, has emerged as an important fungal pathogen and became one of the main causes of fungemia in tertiary-care hospitals [5–9]. Although the mortality rate due to this species is generally lower than that reported for other *Candida* species, *C. parapsilosis* complex possesses several distinct features, such as its ability to develop biofilms on intravascular devices, high affinity for parenteral nutrition, and an intrinsic low susceptibility to echinocandins [10–12].

* Correspondence: f.barchiesi@univpm.it

¹Clinica Malattie Infettive; Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I° - G.M. Lancisi - G. Salesi, Ancona, Italy

Full list of author information is available at the end of the article

Table 1 Comparison of epidemiological, clinical characteristics and outcome of patients with BSIs due to *Candida parapsilosis* and *Candida albicans*

| Variables | Patients with BSIs due to: | | P value ^a |
|--|---------------------------------|------------------------------|----------------------|
| | <i>C. parapsilosis</i> (n = 63) | <i>C. albicans</i> (n = 146) | |
| Age (years), median (IQR) ^b | 67 (43–76) | 51 (66–77) | 0.133 |
| Neonates (<3 months) | 1 (2) | 5 (3) | 0.465 |
| Elderly (>65 years) | 32 (51) | 72 (49) | 0.844 |
| Male sex, n (%) | 35 (56) | 91 (63) | 0.358 |
| Ward | | | |
| Internal Medicine, n (%) | 25 (40) | 52 (36) | 0.448 |
| Surgery, n (%) | 17 (27) | 32 (22) | |
| Intensive Care Unit, n (%) | 21 (33) | 62 (43) | |
| Comorbidities, n (%) | 57 (90) | 137 (94) | 0.387 |
| Chronic pulmonary diseases, n (%) ^c | 9 (14) | 11 (8) | 0.127 |
| Haematological malignancy, n (%) | 1 (2) | 8 (5) | 0.203 |
| Cardiovascular diseases, n (%) ^d | 27 (43) | 67 (46) | 0.685 |
| Neurological diseases, n (%) ^e | 10 (16) | 24 (16) | 0.919 |
| Gastrointestinal diseases, n (%) ^f | 21 (33) | 43 (29) | 0.576 |
| Diabetes mellitus, n (%) | 8 (13) | 28 (19) | 0.254 |
| Solid tumors, n (%) | 15 (24) | 43 (30) | 0.403 |
| Chronic renal failure, n (%) | 7 (11) | 12 (8) | 0.504 |
| Previous surgery (<30 days), n (%) | 32 (51) | 67 (46) | 0.514 |
| Gastrointestinal surgery, n (%) | 8 (13) | 19 (13) | 0.950 |
| Cardiovascular surgery, n (%) | 13 (21) | 28 (19) | 0.807 |
| Other surgery, n (%) ^g | 12 (19) | 24 (16) | 0.646 |
| Central venous catheter, n (%) | 56 (89) | 127 (87) | 0.702 |
| BSI CVC-related, n (%) | 36 (64) | 57 (45) | 0.015 |
| Other devices, n (%) ^h | 57 (90) | 129 (88) | 0.653 |
| Previous invasive procedures (<72 h), n (%) ⁱ | 16 (25) | 44 (30) | 0.486 |
| Parenteral nutrition, n (%) | 43 (68) | 105 (72) | 0.592 |
| Immunosuppressive therapy, n (%) ^j | 18 (29) | 56 (34) | 0.174 |
| Neutropenia, n (%) | 4 (6) | 7 (5) | 0.644 |
| Septic shock, n (%) | 2 (3) | 12 (8) | 0.180 |
| Prior antibiotic therapy, n (%) | 58 (92) | 139 (95) | 0.370 |
| Previous antifungal therapy (<30 days), n (%) | 5 (8) | 21 (14) | 0.195 |
| Concomitant bacteriemia, n (%) | 15 (24) | 40 (27) | 0.588 |
| Other coinfections, n (%) ^k | 39 (62) | 89 (61) | 0.897 |
| Appropriate antifungal therapy, n (%) ^l | 38 (60) | 92 (63) | 0.712 |
| Primary azole therapy | 41 (65) | 77 (53) | 0.098 |
| Primary echinocandin therapy | 7 (11) | 34 (23) | 0.041 |
| Primary polyene therapy | 1 (2) | 3 (2) | 0.820 |
| None | 14 (22) | 32 (22) | 0.961 |

Table 1 Comparison of epidemiological, clinical characteristics and outcome of patients with BSIs due to *Candida parapsilosis* and *Candida albicans* (Continued)

| | | | |
|-----------------------------------|---------|---------|-------|
| Overall mortality, n (%) | 17 (27) | 61 (42) | 0.042 |
| Early mortality (days 1–7), n (%) | 4 (6) | 24 (17) | 0.049 |
| Late mortality (days 8–30), n (%) | 13 (21) | 37 (25) | 0.464 |

^aComparisons between groups were performed using Wilcoxon rank sum test for quantitative variables and Chi-Square test (or Fisher Exact Test when expected frequencies were less than five) for qualitative variables

^bQQR, Interquartile range

^cChronic pulmonary diseases include asthma, chronic bronchitis, emphysema and lung fibrosis

^dCardiovascular diseases include heart failure, ischemic heart disease, endocarditis and arrhythmia

^eNeurological diseases include Parkinson's disease, Alzheimer's disease and paralysis

^fGastrointestinal diseases include Crohn's disease, ulcerative colitis, chronic pancreatitis and gallbladder stones

^gOther surgery includes plastic surgery, thoracic surgery, orthopaedic surgery, urological surgery and neurosurgery

^hOther devices include urinary catheter, surgical drainage, cutaneous gastrostomy and tracheostomy tube

ⁱPrevious invasive procedures include endoscopy and positioning of any device

^jImmunosuppressive therapy include corticosteroids, calcineurin inhibitors and monoclonal antibodies

^kOther coinfections include bacterial and/or fungal infections in sites other than blood

^lAppropriate antifungal therapy was considered when the appropriate drug with adequate dosage was started ≤ 72 h from the first blood culture performed

The aim of this study was to analyze the factors related to outcome of candidemia due to *C. parapsilosis* complex in a single institution over a five-year period.

Methods

Study population and data collection

A retrospective observational study of all cases of candidemia was carried out from January 1, 2010 to December 31, 2014 (5-year period) in a single 980-bedded referral University Hospital in Ancona, Italy. A case of *Candida* BSI was defined as a peripheral isolation of *Candida* species from blood culture in a patient with temporally related clinical signs and symptoms of infection. All *Candida* BSIs were identified through the microbiological laboratory database. Data regarding demographic characteristics and clinical risk factors were collected from the patient's medical records. Appropriate antifungal therapy was considered when an appropriate drug (based on subsequent in vitro susceptibility testing results) with adequate dosage was started within 72 h from the first blood culture performed. Adequate dosage of an antifungal agent was defined according to IDSA 2009 guidelines [13]. Early central venous catheter (CVC) removal was defined a removal of the line within 48 h from drawing blood culture. Mortality was calculated after 7 and 30 days from the occurrence of the episode of *Candida* BSI.

Candida species were isolated from blood samples using BacT/ALERT (bioMérieux) and identified with standard techniques. Each of the three species of *C. parapsilosis* sensu lato was identified using the MALDI-TOF Biotyper™ [14]. Antifungal susceptibility testing was performed using the SensitreYeastOne colorimetric plate (SYO) (Trek Diagnostic System) and MIC results were interpreted according to latest species-specific CBPs as established by the CLSI [15].

The present research has been performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. The Institutional

Review Board of the Azienda Ospedaliero-Universitaria Ospedale Riuniti Umberto I°-Lancisi-Salesi granted retrospective access to the data without need for individual informed consent.

Statistical analysis

Quantitative data were shown as the median with interquartile ranges (Q1–Q3). Qualitative variables were expressed as absolute and relative frequencies. Categorical variables were compared using the χ^2 test, whereas Mann–Whitney U test or Fisher exact test were applied for continuous variables. Variables with a $p \leq 0.05$ at the descriptive analysis were analyzed by Cox regression. All statistical analyses were performed using the statistical package SPSS for Windows v. 20 (SPSS Inc., Chicago, IL, USA). A P value of ≤ 0.05 was considered to represent statistical significance and all statistical tests were two-tailed.

Results

Of 270 patients diagnosed with *Candida* BSIs during the study period, 63 (23 %) were infected with isolates of *C. parapsilosis* complex (95 *C. parapsilosis* sensu lato, 3 *C. orthopsilosis* and 2 % *C. metapsilosis*). This species represented the second most frequently isolated yeast after *C. albicans* (146 [54 %]). The remaining infections were due to *C. tropicalis* (23 [9]), *C. glabrata* (10 [4]) and other *Candida* species (10 [4 %]). Although *C. albicans* represented the most commonly isolated species, its percentage significantly decreased from 68 % to 48 % in the time period considered ($p = 0.040$). On the opposite, there was a significant increase of the percentage of *C. parapsilosis* isolation from 8 % (2010) to 30 % (2014) ($p = 0.036$). The overall incidence rate of BSIs due to *C. parapsilosis* was 0.4 episodes/1000 hospital admissions.

Demographics and clinical characteristics of 63 patients infected with isolates of *C. parapsilosis* complex were compared with those of 146 patients infected with

Table 2 Outcome of 63 patients with BSIs due to *Candida parapsilosis* complex considered in this study

| Characteristics | 30-day outcome | | |
|---|-------------------|----------------|----------------------|
| | Survival (n = 46) | Death (n = 17) | P value ^a |
| Age (years), median (IQR) ^b | 62 (31–75) | 76 (63–78) | 0.046 |
| Male sex, n (%) | 24 (52) | 11 (65) | 0.374 |
| Ward | | | |
| Internal Medicine, n (%) | 21 (46) | 4 (24) | 0.033 |
| Surgery, n (%) | 14 (30) | 3 (18) | |
| Intensive Care Unit, n (%) | 11 (24) | 10 (59) | |
| Comorbidities, n (%) | 40(87) | 17(100) | 0.117 |
| Chronic pulmonary diseases, n (%) ^c | 5(11) | 4 (24) | 0.235 |
| Haematological malignancy, n (%) | 1 (2) | 0 (0) | 0.540 |
| Cardiovascular diseases, n (%) ^d | 15 (33) | 12(71) | 0.006 |
| Neurological diseases, n (%) ^e | 9 (20) | 1(6) | 0.263 |
| Gastrointestinal diseases, n (%) ^f | 16 (35) | 5 (29) | 0.688 |
| Diabetes mellitus, n (%) | 4 (9) | 4 (24) | 0.195 |
| Solid tumors, n (%) | 9 (20) | 6 (35) | 0.193 |
| Chronic renal failure, n (%) | 5 (11) | 2 (12) | 1.000 |
| Previous surgery (<30 days), n (%) | 23(50) | 9(53) | 0.835 |
| Gastrointestinal surgery, n (%) | 5(11) | 3(18) | 0.671 |
| Cardiovascular surgery, n (%) | 7(15) | 6(35) | 0.080 |
| Other surgery, n (%) ^g | 11(24) | 1 (6) | 0.154 |
| Central venous catheter, n (%) | 41(89) | 15 (88) | 0.920 |
| BSI CVC-related, n (%) | 25 (61) | 11 (73) | 0.460 |
| Early central venous catheter removal, n (%) ^h | 41 (100) | 11 (73) | <0.0001 |
| Other devices, n (%) ⁱ | 40 (87) | 17(100) | 0.178 |
| Previous invasive procedures (<72 h), n (%) ^j | 9 (20) | 7 (41) | 0.080 |
| Parenteral nutrition, n (%) | 29 (63) | 14 (82) | 0.143 |
| Immunosuppressive therapy, n (%) ^k | 13(28) | 5(29) | 0.920 |
| Neutropenia, n (%) | 3 (7) | 1 (6) | 1.000 |
| Septic shock, n (%) | 1(2) | 1(6) | 0.470 |
| Prior antibiotic therapy, n (%) | 42 (91) | 16 (94) | 0.713 |
| Previous antifungal therapy, n (%) | 4 (9) | 1 (6) | 0.713 |
| Concomitant bacteriemia, n (%) | 12(26) | 3(18) | 0.487 |
| Other coinfections, n (%) ^l | 28 (61) | 11(65) | 0.780 |

Table 2 Outcome of 63 patients with BSIs due to *Candida parapsilosis* complex considered in this study (Continued)

| | | | |
|---|---------|--------|-------|
| Appropriate antifungal therapy ^m | 30 (65) | 8 (47) | 0.190 |
| Primary azole therapy | 32 (70) | 9 (53) | 0.219 |
| Primary echinocandin therapy | 5 (11) | 2 (12) | 1.000 |
| Primary polyene therapy | 1 (2) | 0 (0) | 1.000 |
| None | 8 (17) | 6 (35) | 0.129 |

^aComparisons between groups were performed using Wilcoxon rank sum test for quantitative variables and Chi-Square test (or Fisher Exact Test when expected frequencies were less than five) for qualitative variables

^bIQR, Interquartile range

^cChronic pulmonary diseases include asthma, chronic bronchitis, emphysema and lung fibrosis

^dCardiovascular diseases include heart failure, ischemic heart disease, endocarditis and arrhythmia

^eNeurological diseases include Parkinson's disease, Alzheimer's disease and paralysis

^fGastrointestinal diseases include Crohn's disease, ulcerative colitis, chronic pancreatitis and gallbladder stones

^gOther surgery includes plastic surgery, thoracic surgery, orthopaedic surgery, urological surgery and neurosurgery

^hEarly CVC removal was considered occurring within 48 h from blood cultures drawing

ⁱOther devices include urinary catheter, surgical drainage, cutaneous gastrostomy and tracheostomy tube

^jPrevious invasive procedures include endoscopy and positioning of any device

^kImmunosuppressive therapy include corticosteroids, calcineurin inhibitors and monoclonal antibodies

^lOther coinfections include bacterial and/or fungal infections in sites other than blood

^mAppropriate antifungal therapy was considered when the appropriate drug with adequate dosage was started within 72 h the first blood culture performed

isolates of *C. albicans* and the results are shown in Table 1. Median patients age was 67 years. Male accounted for 56 % of the population. Twenty-five isolates were recovered from patients hospitalized in medical wards, 21 from patients hospitalized in ICUs and 17 from patients hospitalized in surgical wards. The majority of patients (90 %) suffered from multiple comorbidities (range 2 to 4) being the most common cardiovascular (43) and gastrointestinal (33 %) diseases. A total of 51 % of patients underwent a surgical intervention within 30 days from the onset of candidemia. In comparison with *C. albicans*, BSIs due to *C. parapsilosis* were significantly more often associated with the use of CVC ($p = 0.015$). The overall crude mortality at 30 days was higher in patients infected with *C. albicans* than *C. parapsilosis* (42 % vs 27 %, respectively, $p = 0.042$).

Factors related to outcome of 63 patients with BSIs due to *C. parapsilosis* are reported in Table 2. Older age ($p = 0.046$), being hospitalized in ICU or in medical wards rather than in surgical wards ($p = 0.033$), being

recently diagnosed with a cardiovascular disease ($p = 0.006$), and the lack of an early CVC removal ($p = 0.003$) were all factors associated with a significant higher probability of death at the descriptive analysis. On multivariate analysis, being hospitalized in ICU resulted independently associated with a significant higher risk of mortality (HR 4.625 [CI95% 1.015–21.080], $p = 0.048$). Conversely, early CVC removal was confirmed to be significantly associated with a lower risk of mortality (HR 0.299 [CI95% 0.102–0.874], $p = 0.027$).

Table 3 shows the results of antifungal susceptibility testing to nine antifungal agents as routinely performed by the SYO method which was developed to provide an easy alternative to the CLSI procedure. With the exception of one isolate that showed to be susceptible dose dependent to fluconazole (MIC 4 µg/ml) and two isolates which were found to have non-wild type phenotype for flucytosine (MIC 1 µg/ml), all isolates showed to be fully susceptible to all antifungals according to the CLSI interpretation [15].

Table 3 In vitro susceptibilities of *Candida parapsilosis* complex isolates considered in this study

| Antifungal agents | MIC range (µg/ml) | MIC ₅₀ (µg/ml) | MIC ₉₀ (µg/ml) | % of isolates in the indicated category according to CLSI ^a | | | | | |
|-------------------|-------------------|---------------------------|---------------------------|--|-----|---|---|-----|--------|
| | | | | S | SDD | I | R | WT | Non-WT |
| Amphotericin B | ≤0.12–1 | 0.5 | 0.5 | - | - | - | - | 100 | 0 |
| Flucytosine | ≤0.06–1 | ≤0.06 | 0.25 | - | - | - | - | 97 | 3 |
| Fluconazole | ≤0.12–4 | 0.25 | 1 | 98.4 | 1.6 | - | 0 | - | - |
| Itraconazole | ≤0.015–0.25 | 0.06 | 0.12 | - | - | - | - | 100 | 0 |
| Voriconazole | ≤0.008–0.06 | ≤0.008 | 0.015 | 100 | 0 | - | 0 | - | - |
| Posaconazole | ≤0.008–0.12 | 0.03 | 0.06 | - | - | - | - | 100 | - |
| Caspofungin | 0.06–1 | 0.25 | 0.5 | 100 | - | 0 | 0 | - | - |
| Anidulafungin | 0.12–2 | 0.5 | 2 | 100 | - | 0 | 0 | - | - |
| Micafungin | 0.12–2 | 1 | 2 | 100 | - | 0 | 0 | - | - |

^aCategory was interpreted according to CLSI breakpoints as reported in ref. 15. S, susceptible; SDD susceptible dose dependent, I intermediate, R resistant, WT wild type

Discussion and conclusions

Although *C. albicans* remains the most common fungal isolate from blood, longitudinal studies showed a trend toward an increased prevalence of other *Candida* spp. with a larger proportion of *C. glabrata* in the United States and *C. parapsilosis* in some European (i.e.: Italy or Spain) and Latin American countries [3–9]. As far, few studies focused on the specific predictors influencing the outcome of BSIs due to *C. parapsilosis* [16–18].

First, we confirmed that the mortality due to this species is somewhat lower than that reported for *C. albicans*, having found a rate of 27 % at 30 days. This figure is consistent with literature data in which the 30-day mortality due to this species ranges from 23 % to 30 % [14, 19–21].

Second, hospitalization in ICU showed to be independently associated with higher risk of mortality. Our data are in agreement with a large study showing a mortality rate increasing from 29 % to 47 % in patients with BSIs due to *Candida* spp. hospitalized, respectively, in non-ICU and ICU wards [22]. ICU stay would represent a surrogate marker of illness severity thereby facilitating the poor outcome of this population group.

Third, we showed that early CVC removal is protective in BSIs due to *C. parapsilosis*. Although the impact of CVC management has been extensively investigated on the outcome of patients with candidemia, few studies have examined this issue across individual *Candida* species. Two recent studies showed that CVC removal exerted a protective effect on the outcome of candidemia due to *C. parapsilosis* [14, 20]. Since this species is characterized by a high propensity to develop biofilms on intravascular devices, their early removal play a fundamental role in determining the outcome of infection.

Fourth, we found that the outcome was not influenced by an appropriate antifungal therapy. Despite this finding is somewhat divergent from that reported by the current literature [23–25], there is a paucity of data considering the infection outcome of individual *Candida* species. In this regard, there are two important factors to consider. First, being *C. parapsilosis* less pathogenic than other *Candida* species (i.e.: *C. albicans* and *C. tropicalis*) [17], BSIs due to this entity could be more deeply affected by a correct general management (i.e.: prompt removal of any central line) rather than an early therapeutic intervention. Second, we defined appropriate antifungal therapy as the appropriate drug with adequate dosage started within 72 h from the first blood culture performed. Since *C. parapsilosis* has a time to positivity of blood cultures longer than those reported for *C. albicans* and *C. tropicalis* [26], preliminary blood culture showing the growth of yeast-like fungal pathogen could be delayed thereby determining an initial, although adequate, antifungal treatment after this time interval.

Interestingly, we found that primary antifungal treatment (i.e.: triazoles or echinocandins) did not influence the outcome of *C. parapsilosis* BSIs. Although, this *Candida* species possesses a natural low susceptibility profile to echinocandins [12] and there is still a debate on the use of these molecules in infections caused by this species, either randomized or not-randomized clinical trials have shown not significant differences in the success rates between arms [27–30]. Our data, although with a limited number of patients, corroborated these findings.

The present study have some limitations. First, being a single-center study, the number of patients considered is low. This feature has certainly weakened the statistical power of the study. Nevertheless, we have made all attempts to collect and analyze as many as clinical data as possible to reveal useful information for the management of patients infected with this *Candida* species. Second, being a retrospective study encompassing several departments and medical disciplines over a five years period, there was not a univocal management of each individual case. In this respect, serial follow-up blood cultures were not systematically performed and we were unable to include important parameters, other than 30-day mortality, such as the persistence of positive blood cultures after the initiation of antifungal therapy.

In conclusion, our study shows that candidemia due to *C. parapsilosis* complex, the second most commonly causative agent of yeast BSIs in our center, is characterized by a non-negligible mortality at 30 days. While an early CVC removal is associated with significant reduced mortality, the type of primary antifungal therapy does not influence the outcome. Further prospective studies including higher number of patients are needed to corroborate these findings.

Abbreviations

BSIs, bloodstream infections; CBP, clinical breakpoints; CLSI, Clinical and Laboratory Standards Institute; CVC, central venous catheter; HR, hazard ratio; ICUs, Intensive Care Units; IDSA, Infectious Disease Society of America; MALDI-TOF, Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry; MICs, minimum inhibitory concentrations; Q1-Q3, interquartile range; spp, species; h, hours; SPSS, Statistical Package for the Social Sciences; SYO, SensitreYeastOne colorimetric plate

Availability of data and materials

The data cannot be shared as local Institutional Review Board has no policy to share the data without prior permission.

Authors' contributions

FB designed the study, analyzed data and wrote the article. EQ, performed the acquisition of data, analyzed data and wrote the article. PO, CC, and FS, provided the clinical data. EM, provided the laboratory data. All authors drafted the article, revised it critically for important intellectual content, and approved the final article.

Competing interests

The authors declare that they have no competing interests. The authors alone are responsible for the content and the writing of the paper.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The present research has been performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. The Institutional Review Board of the Azienda Ospedaliero-Universitaria Ospedale Riuniti Umberto I°-Lancisi-Salesi granted retrospective access to the data without need for individual informed consent.

Author details

¹Clinica Malattie Infettive; Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I°- G.M. Lancisi – G. Salesi, Ancona, Italy. ²Clinica Pediatrica; Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I°- G.M. Lancisi – G. Salesi, Ancona, Italy. ³Pediatria, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I°- G.M. Lancisi – G. Salesi, Ancona, Italy. ⁴Anestesia e Rianimazione Pediatrica, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I°- G.M. Lancisi – G. Salesi, Ancona, Italy. ⁵Laboratorio di Microbiologia, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I°- G.M. Lancisi – G. Salesi, Ancona, Italy.

Received: 14 June 2016 Accepted: 11 July 2016

Published online: 09 August 2016

References

- Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of *Candida* diseases 2012: non-neutropenic adult patients. *Clin Microbiol Infect.* 2012;18:19–37.
- Lionakis MS, Netea MG. *Candida* and host determinants of susceptibility to invasive candidiasis. *PLoS Pathog.* 2013;9:e1003079.
- Nieto MC, Telleria O, Cisterna R. Sentinel surveillance of invasive candidiasis in Spain: epidemiology and antifungal susceptibility. *Diagn Microbiol Infect Dis.* 2015;81:34–40.
- Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care. *BMC Infect Dis.* 2006;6:21.
- Barchiesi F, Orsetti E, Gesuita R, Skrami E, Manso E, Candidemia Study Group. Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014. *Infection.* 2016;44:205–13.
- Tortorano A, Prigntano A, Lazzarini C, et al. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. *Infection.* 2013;41:655–62.
- Montagna MT, Caggiano G, Lovero G, et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). *Infection.* 2013;41:645–53.
- Trofa D, Gácsér A, Nosanchuk JD. *Candida parapsilosis*, an emerging fungal pathogen. *Clin Microbiol Rev.* 2008;21:606–25.
- Nucci M, Queiroz-Telles F, Alvarado-Matute T, et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. *PLoS One.* 2013;8:e59373.
- Cantòn E, Pemàn J, Quindòs G, et al. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of *Candida parapsilosis*, *Candida orthopsilosis*, and *Candida metapsilosis* isolated from patients with candidemia. *Antimicrob Agents Chemother.* 2011;55:5590–6.
- Borghi E, Sciota R, Iatta R, et al. Characterization of *Candida parapsilosis* complex strains isolated from invasive fungal infections. *Eur J Clin Microbiol Infect Dis.* 2011;30:1437–4.
- Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and *Candida* revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. *Drug Resist Updat.* 2011;14:164–76.
- Pappas PG, CA K m, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2009;48:503–35.
- Chen CY, Sheng WH, Huang SY, et al. Clinical characteristics and treatment outcomes of patients with candidemia due to *Candida parapsilosis* sensu lato species at a medical centre in Taiwan, 2000–12. *J Antimicrob Chemother.* 2015;70:1531–8.
- Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of *Candida* spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. *J Clin Microbiol.* 2012;50:2846–56.
- Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. *Clin Infect Dis.* 2012;54:1110–22.
- Girmenia C, Martino P, De Bernardis F, et al. Rising incidence of *Candida parapsilosis* fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. *Clin Infect Dis.* 1996;23:506–14.
- Miranda LD, Rodrigues EC, Costa SF, et al. *Candida parapsilosis* candidaemia in a neonatal unit over 7 years: a case series study. *BMJ Open.* 2012;24: 10.1136/bmjopen-2012-000992.
- Almirante B, Rodríguez D, Cuenca-Estrella M, et al. Epidemiology, risk factors, and prognosis of *Candida parapsilosis* bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. *J Clin Microbiol.* 2006;44:1681–5.
- Fernández-Ruiz M, Aguado JM, Almirante B, et al. Initial use of echinocandins does not negatively influence outcome in *Candida parapsilosis* bloodstream infection: a propensity score analysis. *Clin Infect Dis.* 2014;58:1413–21.
- Fortún J, Martín-Dávila P, Gómez-García de la Pedrosa E, et al. Emerging trends in candidemia: a higher incidence but a similar outcome. *J Infect.* 2012;65:64–70.
- Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin Infect Dis.* 2004;39:309–17.
- Bassetti M, Molinari MP, Mussap M, Viscoli C, Righi E. Candidemia in internal medicine departments: the burden of a rising problem. *Clin Microbiol Infect.* 2013;19:e281–4.
- Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi institutional study. *Clin Infect Dis.* 2006;43:25–31.
- Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of *Candida* bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. *Antimicrob Agents Chemother.* 2005;49:3640–5.
- Kim SH, Yoon YK, Kim MJ, Sohn JW. Clinical impact of time to positivity for *Candida* species on mortality in patients with candidaemia. *J Antimicrob Chemother.* 2013;68:2890–7.
- Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. *N Engl J Med.* 2002;347:2020–9.
- Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. *N Engl J Med.* 2007;356:2472–82.
- Kuse ER, Chetchotiskad P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. *Lancet.* 2007;369:1519–27.
- Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. *Clin Infect Dis.* 2007;45:883–93.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

